The FTO opportunity is the CPACS opportunity.
If the likelihood of Bisantrene having an FTO-inhibitor competitor was 10% in the next 4-years, then a CPACS competitor is 0.1%.
A CPACS drug doesn't need to have FTO-inhibition as it's anti-cancer synergy, but Bisantrene does. Pure FTO-inhibition is potentially cardiotoxic in synergy with other drugs. FTO-inhibition as your anti-cancer synergy is good because it plays a central role in almost all cancer types and resistance across a broad spectrum of therapies.
Bisantrene synergising with Doxorubicin to more effectively kill cancer proves FTO as a valid therapy target, and validates all the preclinical studies supporting the combination of FTO-inhibitors with 26 drug classes. Doxorubicin is the most-dosed drug globally, so piggybacking off 10% of it's dosing each year is worth hundreds of millions or even billions in sales. Pharma companies want first-in-class drugs with huge markets and no competition.
- Forums
- ASX - By Stock
- Pillar 1 - FTO (new thread)
The FTO opportunity is the CPACS opportunity. If the likelihood...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.83 |
Change
0.020(1.11%) |
Mkt cap ! $310.7M |
Open | High | Low | Value | Volume |
$1.81 | $1.83 | $1.79 | $142.0K | 78.77K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.83 | 641 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.810 |
3 | 7009 | 1.790 |
1 | 450 | 1.780 |
1 | 651 | 1.775 |
3 | 17043 | 1.770 |
Price($) | Vol. | No. |
---|---|---|
1.825 | 641 | 1 |
1.830 | 1209 | 2 |
1.835 | 651 | 1 |
1.840 | 4651 | 3 |
1.845 | 2746 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online